The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Andrea Herencia-Ropero(Universitat Autònoma de Barcelona), Violeta Serra(Vall d'Hebron Institut de Recerca)
Cited by 58
Related Papers
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
|Oncogene|2011|534
Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
|Cancer Research|2022|94
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts
|npj Precision Oncology|2025|0